Predictors associated with a better response to the Japanese aluminum-free hepatitis A vaccine, Aimmugen, for people living with HIV.
Predictors associated with a better response to the Japanese aluminum-free hepatitis A vaccine, Aimmugen, for people living with HIV.
复制标题
与艾滋病毒感染者对日本无铝甲型肝炎疫苗 Aimmugen 产生更好反应相关的预测因素。
DOI：
10.1111/hepr.13736
复制
发表时间：
2021
影响因子：
4.2
通讯作者：
Yotsuya
中科院分区：
文献类型：
--
作者：
Koga Michiko;Senkoji Tomoe;Kubota Megumi;Ishizaka Aya;Mizutani Taketoshi;Sedohara Ayako;Ikeuchi Kazuhiko;Kikuchi Tadashi;Adachi Eisuke;Saito Makoto;Koibuchi Tomohiko;Hosomichi Kazuyoshi;Ohashi Jun;Kawana‐Tachikawa Ai;Matano Tetsuro;Tsutsumi Takeya;Yotsuya
目的2018年左右，男性性行为者（MSM）中爆发甲型肝炎病毒（HAV）后，人们强调了HAV疫苗接种的重要性，特别是对携带人类免疫缺陷病毒（MSM‐LWHIV）的MSM。Aimmugen®在日本独家授权和分销。虽然建议接种三剂，但据报道，一般人群中85%的接种者在第二剂后获得了血清保护。在这项研究中，我们评估了两个或三个疫苗剂量沿着的有效性与Aimmugen®在MSM-LWHIV.MethodsWe的反应相关的预测因素回顾性检查抗HA-IgG滴度的MSM-LWHIV接种Aimmugen®在我们的医院。从病历中收集患者的数据。结果在2018年1月至2019年10月期间，对141名中位年龄为46岁的受试者进行了检查。所有受试者均接受抗逆转录病毒治疗（ART），中位CD 4计数为615/μL。第二次和第三次给药后可保护抗HA IgG滴度的获得率分别为71.1%和98.6%。在第二次给药后检测抗HA IgG滴度的114例受试者中，与更好应答显著相关的因素是ART持续时间延长和CD 4计数较高。第三次剂量后的抗HA IgG滴度在第二次剂量后血清反应阳性的人中高于那些没有的人。结论三次剂量的Aimmugen®对MSM-LWHIV有效，而两次剂量与非HIV感染者相比效果较差。ART持续时间较短且CD 4细胞计数较少的LWHIV人群抗HA-IgG滴度较低，可能需要额外接种疫苗。
AimAfter the hepatitis A virus (HAV) outbreak among men who have sex with men (MSM) around 2018, the importance of HAV vaccination was emphasized, especially for MSM‐living with human immunodeficiency virus (MSM‐LWHIV). Aimmugen®is licensed and distributed exclusively in Japan. While administration of three doses is recommended, 85% of recipients in the general population were reported to acquire seroprotection after the second dose. In this study, we evaluated the efficacy of two or three vaccine doses along with predictors associated with the response to Aimmugen®in MSM‐LWHIV.MethodsWe retrospectively examined anti‐HA‐IgG titers of MSM‐LWHIV vaccinated with Aimmugen®in our hospital. Patients' data were collected from medical records.ResultsBetween January 2018 and October 2019, 141 subjects whose median age was 46 years old, were examined. All the subjects were on antiretroviral therapy (ART) and the median CD4 count was 615/μL. The acquisition rate of protectable anti‐HA‐IgG titers after the second and third dose was 71.1% and 98.6%, respectively. In 114 subjects whose anti‐HA‐IgG titers were tested after the second‐dose, factors significantly associated with better response were prolonged ART duration and higher CD4 count. The titers of anti‐HA‐IgG after the third dose were higher in those who became seropositive after the second‐dose than those who did not.ConclusionsThree‐dose of Aimmugen®for MSM‐LWHIV was effective while two‐dose was less effective compared to non‐HIV‐infected people. People‐LWHIV with shorter duration of ART and lesser CD4 cell count achieved lower titers of anti‐HA‐IgG and might require an additional vaccination.